BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 28676912)

  • 1. Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression.
    Takanashi S; Aisa Y; Ito C; Arakaki H; Osada Y; Amano Y; Hirano M; Nakazato T
    Rheumatol Int; 2017 Oct; 37(10):1629-1633. PubMed ID: 28676912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders.
    Tokuhira M; Tanaka Y; Takahashi Y; Kimura Y; Tomikawa T; Anan T; Watanabe J; Sagawa M; Higashi M; Momose S; Amano K; Tabayashi T; Nakaseko R; Tamaru JI; Kizaki M
    J Clin Exp Hematop; 2020 Jun; 60(2):41-50. PubMed ID: 32404570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate.
    Saito S; Kaneko Y; Yamaoka K; Tokuhira M; Takeuchi T
    Rheumatology (Oxford); 2017 Jun; 56(6):940-946. PubMed ID: 28165538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal.
    Inui Y; Matsuoka H; Yakushijin K; Okamura A; Shimada T; Yano S; Takeuchi M; Ito M; Murayama T; Yamamoto K; Itoh T; Aiba K; Minami H
    Leuk Lymphoma; 2015; 56(11):3045-51. PubMed ID: 25721751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders.
    Takanashi S; Nakazato T; Aisa Y; Ito C; Arakaki H; Osada Y; Hirano M; Mori T
    Ann Hematol; 2018 Sep; 97(9):1611-1618. PubMed ID: 29713747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
    Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K
    Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Methotrexate-associated lymphoproliferative disorders: clinical aspects].
    Tokuhira M; Kizaki M
    Rinsho Ketsueki; 2019; 60(8):932-943. PubMed ID: 31484893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
    Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
    Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.
    Nakano K; Saito K; Nawata A; Hanami K; Kubo S; Miyagawa I; Fujino Y; Nakayamada S; Tanaka Y
    Mod Rheumatol; 2021 Jan; 31(1):94-100. PubMed ID: 32159414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
    Salloum E; Cooper DL; Howe G; Lacy J; Tallini G; Crouch J; Schultz M; Murren J
    J Clin Oncol; 1996 Jun; 14(6):1943-9. PubMed ID: 8656264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous Regression of Methotrexate-related Lymphoproliferative Disorder with T-cell Large Granular Lymphocytosis.
    Ureshino H; Kadota C; Kurogi K; Miyahara M; Kimura S
    Intern Med; 2015; 54(17):2235-9. PubMed ID: 26328653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report.
    Toyonaga H; Fukushima M; Shimeno N; Inokuma T
    BMC Gastroenterol; 2019 Apr; 19(1):62. PubMed ID: 31023238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.
    Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K
    J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate-related lymphoproliferative disorder of the stomach in a patient with rheumatoid arthritis: a case of disease regression after methotrexate cessation.
    Ikeda K; Nakamura T; Kinoshita T; Fujiwara M; Uose S; Someda H; Miyoshi T; Io K; Nagai K
    Clin J Gastroenterol; 2016 Feb; 9(1):17-21. PubMed ID: 26733461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis.
    Yoshida Y; Takahashi Y; Yamashita H; Kano T; Kaneko H; Mimori A
    Mod Rheumatol; 2014 Sep; 24(5):763-5. PubMed ID: 24498893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: Comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types.
    Gion Y; Iwaki N; Takata K; Takeuchi M; Nishida K; Orita Y; Tachibana T; Yoshino T; Sato Y
    Cancer Sci; 2017 Jun; 108(6):1271-1280. PubMed ID: 28380678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.
    Kurita D; Miyoshi H; Ichikawa A; Kato K; Imaizumi Y; Seki R; Sato K; Sasaki Y; Kawamoto K; Shimono J; Yamada K; Muto R; Kizaki M; Nagafuji K; Tamaru JI; Tokuhira M; Ohshima K
    Am J Surg Pathol; 2019 Jul; 43(7):869-884. PubMed ID: 31116708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients.
    Kameda T; Dobashi H; Miyatake N; Inoo M; Onishi I; Kurata N; Mitsunaka H; Kawakami K; Fukumoto T; Susaki K; Izumikawa M; Nakashima S; Shimada H; Takeuchi Y; Haba R; Mano S; Onishi H; Imataki O; Matsunaga T
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1302-9. PubMed ID: 24515570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct decrease in peripheral lymphocytes in EBER-positive cases of MTX-LPD.
    Kondo M; Murakawa Y; Moriyama M; Honda M; Sugiura T; Onoda K; Watanabe Y; Kakimaru H
    Mod Rheumatol; 2021 Jan; 31(1):88-93. PubMed ID: 32075469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD).
    Watanabe S; Manabe O; Hirata K; Oyama-Manabe N; Hattori N; Kikuchi Y; Kobayashi K; Toyonaga T; Tamaki N
    BMC Cancer; 2016 Aug; 16():635. PubMed ID: 27528380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.